WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H574844
CAS#: 185039-99-0
Description: PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.
Hodoodo Cat#: H574844
Name: PD 173955-Analog1
CAS#: 185039-99-0
Chemical Formula: C21H14Cl2N4O3
Exact Mass: 440.04
Molecular Weight: 441.268
Elemental Analysis: C, 57.16; H, 3.20; Cl, 16.07; N, 12.70; O, 10.88
Synonym: PD 173955-Analog1
IUPAC/Chemical Name: 3-[[6-(2,6-Dichlorophenyl)-7,8-dihydro-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]benzoic Acid
InChi Key: RBURTLAMOSHNGX-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H14Cl2N4O3/c1-27-18-12(9-14(19(27)28)17-15(22)6-3-7-16(17)23)10-24-21(26-18)25-13-5-2-4-11(8-13)20(29)30/h2-10H,1H3,(H,29,30)(H,24,25,26)
SMILES Code: O=C(O)C1=CC=CC(NC2=NC=C(C=C(C3=C(Cl)C=CC=C3Cl)C(N4C)=O)C4=N2)=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 441.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Zhang J, Wang S, Jiang B, Huang L, Ji Z, Li X, Zhou H, Han A, Chen A, Wu Y, Ma H, Zhao W, Zhao Q, Xie C, Sun X, Zhou Y, Huang H, Suleman M, Lin F, Zhou L, Tian F, Jin M, Cai Y, Zhang N, Li Q. c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis. Nat Commun. 2017 Jan 5;8:13732. doi: 10.1038/ncomms13732. PMID: 28054552; PMCID: PMC5227066.
2. Lou L, Yu Z, Wang Y, Wang S, Zhao Y. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo. Cancer Sci. 2018 May;109(5):1648-1659. doi: 10.1111/cas.13572. Epub 2018 Apr 17. PMID: 29575318; PMCID: PMC5980174.
3. Li J, Hu B, Wang T, Huang W, Ma C, Zhao Q, Zhuo L, Zhang T, Jiang Y. C-Src confers resistance to mitotic stress through inhibition DMAP1/Bub3 complex formation in pancreatic cancer. Mol Cancer. 2018 Dec 15;17(1):174. doi: 10.1186/s12943-018-0919-5. Erratum in: Mol Cancer. 2019 Nov 29;18(1):172. PMID: 30553276; PMCID: PMC6295060.